최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기BMB reports, v.47 no.4, 2014년, pp.215 - 220
Kwon, Sanghoon (Center for Medical Science Research, College of Medicine, Hallym University) , Kim, Young-Eun (Department of Biochemistry, College of Natural Sciences, Chungbuk National University) , Park, Jeong-A (Department of Biochemistry, College of Natural Sciences, Chungbuk National University) , Kim, Doo-Sik (Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University) , Kwon, Hyung-Joo (Center for Medical Science Research, College of Medicine, Hallym University) , Lee, Younghee (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Molecular-targeted therapy has gained attention because of its high efficacy and weak side effects. Previously, we confirmed that transmembrane 4 superfamily member 5 protein (TM4SF5) can serve as a molecular target to prevent or treat hepatocellular carcinoma (HCC). We recently extended the applica...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
1 Abbas A. Lichtman A. Pillai S. Cellular and molecular immunology Saunders, Elsevier Philadelphia, U.S.A. (2010) 6th ed. 351 373
2 Aly H. A. Cancer therapy and vaccination. J. Immunol. Methods (2012) 382 1 23 10.1016/j.jim.2012.05.014 22658969
3 Montomoli E. Piccirella S. Khadang B. Mennitto E. Camerini R. De Rosa A. Current adjuvants and new perspectives in vaccine formulation. Expert. Rev. Vaccines (2011) 10 1053 1061 10.1586/erv.11.48 21806399
4 Krieg A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. (2002) 20 709 760 10.1146/annurev.immunol.20.100301.064842 11861616
5 Klinman D. M. Currie D. Gursel I Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. (2004) 199 201 216 10.1111/j.0105-2896.2004.00148.x 15233736
6 Bode C. Zhao G. Steinhagen F. Kinjo T. Klinman D. M. CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines (2011) 10 499 511 10.1586/erv.10.174 21506647
7 Davis H. L. Weeratna R. Waldschmidt T. J. Tygrett L. Schorr J. Krieg A. M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. (1998) 160 870 876 9551923
8 Carson D. A. Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. (1997) 186 1621 1622 10.1084/jem.186.10.1621 9411016
9 Chu R. S. Targoni O. S. Krieg A. M. Lehmann P. V. Harding C. V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. (1997) 186 1623 1631 10.1084/jem.186.10.1623 9362523
10 Lee K. W. Jung J. Lee Y. Kim T. Y. Choi S. Y. Park J. Kim D. S. Kwon H. J. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol. Immunol. (2006) 43 2107 2118 10.1016/j.molimm.2005.12.004 16442622
12 Kim D. Kwon S. Rhee J. W. Kim K. D. Kim Y. E. Park C. S. Choi M. J. Suh J. G. Kim D. S. Lee Y. Kwon H. J. Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol. (2011) 12 29 10.1186/1471-2172-12-29 21592346
14 Lee Y. Kwon H. J. Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice. Oncoimmunology. (2012) 1 1215 1217 10.4161/onci.20404 23170285
15 Llovet J. M. Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 48 1312 1327 10.1002/hep.22506 18821591
16 Tanaka S. Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J. Gastroenterol. (2011) 46 289 296 10.1007/s00535-011-0387-9 21350811
17 Muller-Pillasch F. Wallrapp C. Lacher U. Friess H. Buchler M. Adler G. Gress T. M. Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene (1998) 208 25 30 10.1016/S0378-1119(97)00633-1 9479038
18 Lee S. A. Lee S. Y. Cho I. H. Oh M. A. Kang E. S. Kim Y. B. Seo W. D. Choi S. Nam J. O. Tamamori-Adachi M. Kitajima S. Ye S. K. Kim S. Hwang Y. J. Kim I. S. Park K. H. Lee J. W. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J. Clin. Invest. (2008) 118 1354 1366 10.1172/JCI33768 18357344
19 Lee S. A. Ryu H. W. Kim Y. M. Choi S. Lee M. J. Kwak T. K. Kim H. J. Cho M. Park K. H. Lee J. W. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology (2009) 49 1316 1325 10.1002/hep.22777 19177595
20 Kwon S. Kim D. Park B. K. Cho S. Kim K. D. Kim Y. E. Park C. S. Ahn H. J. Seo J. N. Choi K. C. Kim D. S. Lee Y. Kwon H. J. Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One. (2012) 7 e33121 10.1371/journal.pone.0033121 22427965
21 Kwon S. Kim D. Park B. K. Wu G. Park M. C. Ha Y. W. Kwon H. J. Lee Y. Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol. Rep. (2013) 29 735 740 23138455
22 Kwon S. Kim Y. E. Kim D. Park B. K. Wu G. Kim T. H. Choi S. H. Kim D. S. Kwon H. J. Lee Y. Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model. Biochem. Biophys. Res. Commun. (2013) 435 134 139 10.1016/j.bbrc.2013.04.057 23624388
23 Schreiber T. H. Raez L. Rosenblatt J. D. Podack E. R. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol. (2010) 22 105 112 10.1016/j.smim.2010.02.001 20226686
24 Yoshiji H. Kuriyama S. Kawata M. Yoshii J. Ikenaka Y. Noguchi R. Nakatani T. Tsujinoue H. Fukui H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. (2001) 7 1073 1078 11309359
26 Mercurio A. M. Lipscomb E. A. Bachelder R. E. Non-angiogenic functions of VEGF in breast cancer. J. Mammary Gland Biol. Neoplasia. (2005) 10 283 290 10.1007/s10911-006-9001-9 16924371
27 Choi S. Lee S. A. Kwak T. K. Kim H. J. Lee M. J. Ye S. K. Kim S. H. Kim S. Lee J. W. Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood (2009) 113 1845 1855 10.1182/blood-2008-05-160671 19036703
28 Yoshiji H. Kuriyama S. Ways D. K. Yoshii J. Miyamoto Y. Kawata M. Ikenaka Y. Tsujinoue H. Nakatani T. Shibuya M. Fukui H. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. (1999) 59 4413 4418 10485491
※ AI-Helper는 부적절한 답변을 할 수 있습니다.